Background and objectives: Addition of aldosterone antagonists (AA) might provide renal
benefits to proteinuric chronic kidney disease (CKD) patients over and above the inhibition
of renin-angiotensin system blockers (RAS). We evaluated the benefits and harms of adding
selective and nonselective AA in CKD patients already on RAS.